Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
It targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, providing a more comprehensive approach to controlling blood sugar and body weight
(2023) New England Journal of Medicine n=338 Phase 2 trial showing retatrutide produced up to 24.2% body weight loss at 48 weeks, surpassing tirzepatide results
*Disclaimer* This video is for entertainment, education, and informational purposes only
declares having received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka and Tsumura
Support for Long-Term Success Our goal isnt quick weight loss its maintainable weight loss
